<li>alfentanil<p>alfentanil, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>amitriptyline<p>sertraline and amitriptyline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>amoxapine<p>sertraline and amoxapine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>apixaban<p>sertraline and apixaban both increase  anticoagulation. Avoid or Use Alternate Drug.</p></li><li>axitinib<p>sertraline increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary .</p></li><li>bosutinib<p>sertraline increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>buspirone<p>sertraline and buspirone both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>citalopram<p>citalopram and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug. Combination may increase risk of serotonin syndrome or neuroleptic malignant syndrome-like reactions.</p></li><li>clomipramine<p>sertraline and clomipramine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>cobimetinib<p>sertraline will increase the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).</p></li><li>cyclobenzaprine<p>sertraline and cyclobenzaprine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>desipramine<p>sertraline and desipramine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>desvenlafaxine<p>sertraline and desvenlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>dextromethorphan<p>sertraline and dextromethorphan both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>dolasetron<p>dolasetron, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>dosulepin<p>sertraline and dosulepin both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>doxepin<p>sertraline and doxepin both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>duloxetine<p>sertraline will increase the level or effect of duloxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>duloxetine and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>eliglustat<p>sertraline increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .</p></li><li>escitalopram<p>escitalopram and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl<p>sertraline will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.<span><br><br></span>fentanyl, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl intranasal<p>sertraline will increase the level or effect of fentanyl intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.<span><br><br></span>fentanyl intranasal, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl iontophoretic transdermal system<p>sertraline will increase the level or effect of fentanyl iontophoretic transdermal system by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.<span><br><br></span>fentanyl iontophoretic transdermal system, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl transdermal<p>sertraline will increase the level or effect of fentanyl transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.<span><br><br></span>fentanyl transdermal, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fentanyl transmucosal<p>sertraline will increase the level or effect of fentanyl transmucosal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.<span><br><br></span>fentanyl transmucosal, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fluoxetine<p>sertraline will increase the level or effect of fluoxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>fluoxetine and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>fluvoxamine<p>sertraline will increase the level or effect of fluvoxamine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>fluvoxamine and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>granisetron<p>granisetron, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>hydromorphone<p>hydromorphone, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>imipramine<p>sertraline and imipramine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>irinotecan<p>sertraline will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>irinotecan liposomal<p>sertraline will increase the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.</p></li><li>ivabradine<p>sertraline will increase the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inhibitors.</p></li><li>ivacaftor<p>ivacaftor increases levels of sertraline by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Ivacaftor and its M1 metabolite has the potential to inhibit P-gp, may significantly increase systemic exposure to P-gp substrates.</p></li><li>levomilnacipran<p>levomilnacipran and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>linezolid<p>linezolid and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.</p></li><li>lofepramine<p>sertraline and lofepramine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>lorcaserin<p>sertraline and lorcaserin both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>maprotiline<p>sertraline and maprotiline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>mefloquine<p>mefloquine increases toxicity of sertraline by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.</p></li><li>meperidine<p>sertraline and meperidine both increase  serotonin levels. Avoid or Use Alternate Drug.<span><br><br></span>meperidine, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>methylene blue<p>methylene blue and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.</p></li><li>metoclopramide<p>metoclopramide and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactions</p></li><li>mianserin<p>sertraline and mianserin both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>milnacipran<p>milnacipran and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>morphine<p>morphine, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>naloxegol<p>sertraline will increase the level or effect of naloxegol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministation of naloxegol with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDay</p></li><li>nefazodone<p>nefazodone and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>netupitant/palonosetron<p>netupitant/palonosetron, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>nortriptyline<p>sertraline and nortriptyline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>olaparib<p>sertraline will increase the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg PO BID</p></li><li>ondansetron<p>ondansetron and sertraline both increase  QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.<span><br><br></span>ondansetron, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>palonosetron<p>palonosetron, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>paroxetine<p>sertraline will increase the level or effect of paroxetine by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.<span><br><br></span>paroxetine and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>phentermine<p>sertraline, phentermine.
Either increases toxicity of the other by Mechanism: unknown. Avoid or Use Alternate Drug. Risk of serotonin syndrome.</p></li><li>protriptyline<p>sertraline and protriptyline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>rasagiline<p>rasagiline and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.</p></li><li>remifentanil<p>remifentanil, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>selegiline transdermal<p>selegiline transdermal and sertraline both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>st john's wort<p>sertraline and st john's wort both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>sufentanil<p>sufentanil, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>sufentanil sl<p>sufentanil sl, sertraline.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>tedizolid<p>tedizolid, sertraline.
Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.</p></li><li>thioridazine<p>sertraline will increase the level or effect of thioridazine by  affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.</p></li><li>trazodone<p>sertraline and trazodone both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>trimipramine<p>sertraline and trimipramine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>umeclidinium bromide/vilanterol inhaled<p>sertraline increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.</p></li><li>venetoclax<p>sertraline will increase the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If a moderate CYP3A inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities.</p></li><li>venlafaxine<p>sertraline and venlafaxine both increase  serotonin levels. Avoid or Use Alternate Drug.</p></li><li>vilanterol/fluticasone furoate inhaled<p>sertraline increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.</p></li><li>vilazodone<p>sertraline, vilazodone.
Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated.  .</p></li><li>vortioxetine<p>sertraline increases toxicity of vortioxetine by serotonin levels. Avoid or Use Alternate Drug.</p></li><li>warfarin<p>sertraline increases levels of warfarin by decreasing metabolism. Avoid or Use Alternate Drug.</p></li>